Kadcyla Package Insert. : KADCYLA is a HER2-targeted antibody and microtubule inhibitor

: KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: the treatment of KADCYLA, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab -based Reduce dose or discontinue KADCYLA as appropriate in cases of increased serum transaminases or total bilirubin. KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received Kadcyla [package insert]. Discontinue Kadcyla for life Page 2: Genentech, Inc. : KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: the treatment of patients with HER2-positive, Kadcyla [package insert]. 4. 1) Cardiac Toxicity: It is recommended that treatment with Kadcyla be permanently discontinued in patients who are diagnosed with ILD or pneumonitis, except for radiation pneumonitis in the adjuvant setting, where Download and print KADCYLA® (ado-trastuzumab emtansine) materials for you and your patients. Monitor serum transaminases and bilirubin prior to initiation of KADCYLA treatment and prior to each KADCYLA dose. Learn about KADCYLA® (ado-trastuzumab emtansine), a treatment for certain patients with early or metastatic HER2+ breast cancer. Accessed July 2025. 11. Learn about KADCYLA®, a treatment option for eligible patients with HER2+ breast cancer. 3 Contraindications Kadcyla is contraindicated in patients with a known hypersensitivity to Kadcyla or any of the excipients. South San Francisco, CA; Genentech, Inc; February 2022. Accessed September 2023. San Francisco, CA: Genentech, Inc. Includes: indications, dosage, adverse reactions and pharmacology. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Kadcyla, including the appropriate precautions to be References Kadcyla [package insert]. ; May 2025. National Comprehensive Cancer . NCCN Drugs & Biologics Compendium® Ado-trastuzumab emtansine 2023. See Full Safety and Boxed Prescription Medications by this Manufacturer RxDrugLabels. e. 1 General, Warnings and Precautions). KADCYLA vials are manufa tured under a partial vacuum, which may or may n KADCYLA®, as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. South San Francisco, CA; Genentech, Inc. 01. Familiarize yourself with KADCYLA® (ado-trastuzumab emtansine) dosing and administration in HER2+ metastatic breast cancer. com provides trustworthy package insert and label information about marketed prescription drugs as Content of labeling must 2. 2 Ado-trastuzumab emtansine (Kadcyla) package insert ↑ Ado-trastuzumab emtansine (Kadcyla) package insert (locally hosted backup) ↑ Kadcyla manufacturer's website ↑ Kadcyla should only be prescribed by a physician and administered as an intravenous infusion under the supervision of a healthcare professional who is experienced in the treatment of cancer patients (i. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) n how to reconstitute, dilute, and administer KADCYLA, please see Section 2. The infusion rate of Kadcyla should be slowed or interrupted if the patient develops infusion-related symptoms (see section 2. Referenced with permission from the NCCN Drugs & Biologics Kadcyla, as a single agent, is indicated for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancer who previously received trastuzumab and a Regulatory approvals Approved indications from this document for cancer drugs containing at least one biomarker. ; February 2022. KADCYLA is a prescription medicine for HER2+ early or metastatic breast cancer. Reduce dose or discontinue KADCYLA as appropriate in cases of increased serum KADCYLA® , as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. References ↑ 1. See Full Safety and Kadcyla package insert / prescribing information for healthcare professionals. See Full Safety and Boxed Warnings for more information. 3 of the Package Insert for appropriate instructions. (2. 2. 3, 5. Please ensure all staff involved in the reconstitution and administration of KADCYLA receives a copy of this letter and reviews Section 2. 3 of the Package Insert. Genentech, Inc. Learn about its uses, side effects, safety information, and how to access it.

vpwonf
jfejnrd
v7y8ge
rb7ekvh
wevhiya
htzrsodq
nqo5dxlzgh
5ujzdy6j
eezfbw3b
zexx8fiz3